Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel‐Mediated Reprogramming of Cancer‐Associated Fibroblasts in Osteosarcoma
Advanced Materials · 2024-04 · 36 (15)
DOI: 10.1002/adma.202309591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 29.12.2023. Verfasst von Hui Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Technology, Beijing Institute of Technology, Beijing, 100081, China. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Osteosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Beijing Institute of Technology Research Fund Program for Young Scholars.
Abstract (Originalsprache)
In osteosarcoma, immunotherapy often faces hurdles posed by cancer‐associated fibroblasts (CAFs) that secrete dense extracellular matrix components and cytokines. Directly removing CAFs may prove ineffective and even promote tumor metastasis. To address this challenge, a sequential nanocomposite hydrogel that reshapes CAF behavior is developed, enhancing tumor‐infiltrating T‐cells in osteosarcoma. The approach utilizes an injectable blend of carboxymethyl chitosan and tetrabasic polyethylene glycol, forming a hydrogel for controlled release of a potent CAF suppressor (Nox4 inhibitor, Nox4 i ) and liposomal Doxorubicin (L‐Dox) to induce immunogenic cell death (ICD) upon in situ administration. Nox4 i effectively counters CAF activation, overcoming T‐cell exclusion mechanisms, followed by programmed L‐Dox release for ICD induction in stroma‐rich osteosarcoma models. Combining the co‐delivery gel with αPD‐1 checkpoint inhibitor further enhances its effectiveness in an orthotopic osteosarcoma model. Immunophenotyping data underscore a significant boost in tumor T‐cell infiltration and favorable anti‐tumor immunity at the whole‐animal level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medical Technology, Beijing Institute of Technology, Beijing, 100081, China.
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, 100190, China.
- School of Materials Science and Engineering, Beijing Institute of Technology, Beijing, 100081, China.
- Musculoskeletal Tumor Center, Beijing Key Laboratory of Musculoskeletal Tumor, Peking University People's Hospital, Beijing, 100044, China.
- Qiushi College, Beijing Institute of Technology, Beijing, 100081, China.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Beijing Institute of Technology Research Fund Program for Young Scholars
- Peking University People's Hospital Scientific Research Development Funds
- The CAS Project for Young Scientists in Basic Research
Zitieren
APA
Wang, H., Chen, Y., Wei, R., Zhang, J., Zhu, J., Wang, W., Wang, Z., Wupur, Z., Li, Y., & Meng, H. (2024). Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel‐Mediated Reprogramming of Cancer‐Associated Fibroblasts in Osteosarcoma. Advanced Materials, 36(15). https://doi.org/10.1002/adma.202309591
Vancouver
Wang H, Chen Y, Wei R, Zhang J, Zhu J, Wang W, et al. Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel‐Mediated Reprogramming of Cancer‐Associated Fibroblasts in Osteosarcoma. Advanced Materials. 2024;36(15). doi:10.1002/adma.202309591
BibTeX
@article{Wang2024,
author = {Wang, Hui and Chen, Yu and Wei, Ran and Zhang, Jinlong and Zhu, Jiahui and Wang, Wenbin and Wang, Zhenfei and Wupur, Zulpikar and Li, Yujing and Meng, Huan},
title = {Synergistic Chemoimmunotherapy Augmentation via Sequential Nanocomposite Hydrogel‐Mediated Reprogramming of Cancer‐Associated Fibroblasts in Osteosarcoma},
journal = {Advanced Materials},
year = {2024},
volume = {36},
number = {15},
doi = {10.1002/adma.202309591}
}
EUVIMED